|
Anti-CCP titer decrease in adalimumab treated patients: correlation with the clinical response to treatment |
|||||||
| ACR response, week 24 |
Week 0 |
Week 24 |
P |
ACR response, week 48 |
Week 0 |
Week 48 |
P |
|
|
|||||||
| <20% (n = 6) |
118.4 ± 34.9 |
111.8 ± 48.8 |
n.s. |
<20% (n = 3) |
107 ± 14.1 |
68.4 ± 23.3 |
n.d. |
| ACR 20 (n = 21) |
111.5 ± 45.9 |
104.3 ± 48.5 |
n.s. |
ACR 20 (n = 21) |
121.8 ± 48.2 |
88.6 ± 52.6 |
0.001 |
| ACR 50 (n = 16) |
121.9 ± 45.1 |
93.9 ± 46.4 |
0.001 |
ACR 50 (n = 13) |
119.6 ± 45.8 |
73.5 ± 36.2 |
0.001 |
| ACR 70 (n = 3) |
126.8 ± 51.9 |
85.9 ± 43.5 |
n.d. |
ACR 70 (n = 9) |
105.3 ± 37.7 |
65.3 ± 35.5 |
0.003 |
|
46 anti-CCP-positive patients at baseline were included in the evaluation. Results are means ± SD. CCP, cyclic citrullinated peptide; n.d., not done; n.s., not significant. | |||||||
Atzeni et al. Arthritis Research & Therapy 2006 8:R3 doi:10.1186/ar1851 |
|||||||